Status:
COMPLETED
Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis
Lead Sponsor:
Novartis
Conditions:
Atopic Dermatitis
Eligibility:
All Genders
2-11 years
Phase:
PHASE4
Brief Summary
This study is not being conducted in the United States of America (USA). Atopic dermatitis, also called eczema, is characterized by redness, papulation (skin elevation) and pruritus (skin itching). T...
Eligibility Criteria
Inclusion
- Mild to moderate facial atopic dermatitis
- Patients intolerant of, or dependent on, topical corticosteroids
Exclusion
- Concurrent skin diseases (infections)
- Immunocompromised
- Recently received phototherapy or systemic therapy
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
End Date :
August 1 2006
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00130364
Start Date
August 1 2005
End Date
August 1 2006
Last Update
January 15 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
This study is not being conducted in the United States
Novartis Pharmaceuticals, New Jersey, United States